ANTENGENE CORP. DL-0001 (F:722) — Market Cap & Net Worth
Market Cap & Net Worth: ANTENGENE CORP. DL-0001 (722)
ANTENGENE CORP. DL-0001 (F:722) has a market capitalization of $278.87 Million (€238.54 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #15267 globally and #1490 in its home market, demonstrating a -2.22% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ANTENGENE CORP. DL-0001's stock price €0.35 by its total outstanding shares 677662132 (677.66 Million). Also see 722 asset base for a full breakdown of the balance sheet.
ANTENGENE CORP. DL-0001 Market Cap History: 2021 to 2026
ANTENGENE CORP. DL-0001's market capitalization history from 2021 to 2026. Data shows change from $847.72 Million to $278.87 Million (-25.51% CAGR). Also see ANTENGENE CORP. DL-0001 (722) cash conversion ratio for how efficiently the company converts equity into cash flow.
ANTENGENE CORP. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ANTENGENE CORP. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 722 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.98x
ANTENGENE CORP. DL-0001's market cap is 2.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $847.72 Million | $28.77 Million | -$655.53 Million | 29.47x | N/A |
| 2022 | $475.35 Million | $160.13 Million | -$601.49 Million | 2.97x | N/A |
| 2023 | $163.21 Million | $67.31 Million | -$581.18 Million | 2.42x | N/A |
| 2024 | $50.70 Million | $91.95 Million | -$319.25 Million | 0.55x | N/A |
| 2025 | $313.73 Million | $105.34 Million | -$239.13 Million | 2.98x | N/A |
Competitor Companies of 722 by Market Capitalization
Companies near ANTENGENE CORP. DL-0001 in the global market cap rankings as of September 20, 2026. Review ANTENGENE CORP. DL-0001 tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ANTENGENE CORP. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
ANTENGENE CORP. DL-0001 Historical Marketcap From 2021 to 2026
Between 2021 and today, ANTENGENE CORP. DL-0001's market cap moved from $847.72 Million to $ 278.87 Million, with a yearly change of -25.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €278.87 Million | -11.11% |
| 2025 | €313.73 Million | +518.75% |
| 2024 | €50.70 Million | -68.93% |
| 2023 | €163.21 Million | -65.67% |
| 2022 | €475.35 Million | -43.93% |
| 2021 | €847.72 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of ANTENGENE CORP. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $278.87 Million USD |
| MoneyControl | $278.87 Million USD |
| MarketWatch | $278.87 Million USD |
| marketcap.company | $278.87 Million USD |
| Reuters | $278.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more